Besides, inhibition of StAR, with the corresponding decrease in E2 biosynthesis, by a variety of HDACIs, not only in primary cultures of enriched ER+/PR+ mouse breast tumor epithelial cells, but also in MCF7 cells, signifies the potential of StAR as a drug target for treatment of hormone-sensitive BCs. This evidence concerns the gene PGR and breast neoplasm.